Response Financial Statements From 2010 to 2024
Response Oncology financial statements provide useful quarterly and yearly information to potential Response Oncology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Response Oncology financial statements helps investors assess Response Oncology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Response Oncology's valuation are summarized below:Response Oncology does not presently have any trending fundamental ratios for analysis.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Check Response Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Response Oncology's main balance sheet or income statement drivers, such as , as well as many indicators such as . Response financial statements analysis is a perfect complement when working with Response Oncology Valuation or Volatility modules.
Response |
Response Oncology Company Return On Equity Analysis
Response Oncology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Response Oncology Return On Equity | -7.24 |
Most of Response Oncology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Response Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Response Oncology has a Return On Equity of -7.2393. This is much lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Response Oncology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Response Oncology's current stock value. Our valuation model uses many indicators to compare Response Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Response Oncology competition to find correlations between indicators driving Response Oncology's intrinsic value. More Info.Response Oncology is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Response Oncology's earnings, one of the primary drivers of an investment's value.About Response Oncology Financial Statements
Response Oncology investors use historical fundamental indicators, such as Response Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Response Oncology. Please read more on our technical analysis and fundamental analysis pages.
Response Oncology, Inc. does not have significant operations. Prior to the sale of its assets, it provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers under the direction of practicing oncologists owned the assets of and managed the nonmedical aspects of oncology practices compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost plus fee and conducted outcomes research on behalf of pharmaceutical manufacturers. Response Oncology is traded on OTC Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |